Mild Cognitive Impairment, Clinical Characterization and Outcome
Arch Neurol 56:303-308, Petersen,R.C.,et al, 1999
Screening for Dementia with the Memory Impairment Screen
Neurol 52:231-238,224, Buschke,H.,et al, 1999
Preclinical Prediction of Alzheimer's Disease Using SPECT
Neurol 50:1563-1571, Johnson,K.A.,et al, 1998
Genetic Testing of Children at Risk for Huntington's Disease
Neurol 49:1048-1053, Nance,M.A.,et al, 1997
Few Psychological Consequences of Presymptomatic Testing for Huntington Disease
Lancet 349:4, Bundey,S., 1997
The Clinical Introduction of Genetic Testing for Alzheimer Disease, An Ethical Perspective
JAMA 277:832-836, Post,S.G.,et al, 1997
Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the e4Allele for Apolipoprotein E
NEJM 334:752-758, 7911996., Reiman,E.M.,et al, 1996
Motor Changes in Presymptomatic Huntington Disease Gene Carriers
Arch Neurol 53:487-492, Siemers,E.,et al, 1996
High Apolipoprotein E e4 Allele Frequency in Age-Related Memory Decline
Ann Neurol 39:548-551, Blesa,R.,et al, 1996
Statement of Use of Apolipoprotein E Testing for Alzheimer Disease
JAMA 274:1627-1629, Farrer,L.A.,et al, 1995
A Low, "Normal"Score on the Mini-Mental State Exam Predicts Development of Dementia after Three Years
JAGS 43:656-661, Braekhus,A.,et al, 1995
Neuropsychological Detection and Characterization of Preclinical Alzheimer's Disease
Neurol 45:957-962, Jacobs,D.M.,et al, 1995
Reduced Basal Ganglia Volume Associated with the Gene for Huntington's Disease in Asymptomatic at-Risk Persons
Neurol 44:823-828, Aylward,E.H.,et al, 1994
The Neurogenetic Genie:Testing for Huntington's Disease Mutation
Neurol 44:1369-1373, 1533-15361994., Hersch,S.,et al, 1994
A Worldwide Study of the Huntington's Disease Mutation, The Sensitivity & Specificity of Measuring CAG Repeats
NEJM 330:1401-1406, 14501994., Kremer,B.,et al, 1994
Attitudes Toward Direct Predictive Testing for the Huntington Disease Gene
JAMA 270:2321-2325, Babul,R.,et al, 1993
Clinical Consequences of Isolating the Gene for Huntington's Disease
BMJ 307:397-398, Harper,P.S., 1993
Serial Changes of Cerebral Glucose Metab & Caudate Size in Persons at Risk for Huntington's Dis
Arch Neurol 49:1161-1167, Grafton,S.T.,et al, 1992
Presymptomatic Testing for Huntington's Disease in the United Kingdom
BMJ 304:1593-1596, Tyler,A.,et al, 1992
The Psychological Consequences of Predictive Testing for Huntington's Disease
NEJM 327:1401-1405, 14491992., Wiggins,S.,et al, 1992
Genetic Testing for Huntington's Disease
BMJ 300:1089-1090, Harper,P.,et al, 1990
Abnormalities of Striatal Projection Neurons and n-Methyl-d-Aspartate Receptors in Presymptomatic Huntington's Disease
NEJM 322:1293-1298, Albin,R.L.,et al, 1990
Predictive Testing for Huntington's Disease with Linked DNA Markers
Lancet 2:463-466, Brock,D.J.H.,et al, 1989
Problems in Genetic Prediction for Huntington's Disease
Lancet 2:601-603, Morris,M.J.,et al, 1989
Uptake of Presymptomatic Predictive Testing for Huntington's Disease
Lancet 2:603-605, Craufurd,D.,et al, 1989
Predictive Testing for Huntington's Disease, Progress and Problems
BMJ 298:404-405, 1989, Harper,P.S.&Morris,M.J., 1989
Adoption and Genetic Prediction for Huntington's Disease
Lancet 2:1069-1070, Morris,M.,et al, 1988
Predictive Testing for Huntington's Disease with Use of a Linked DNA Marker
NEJM 318:535-542, Meissen,G.J.,et al, 1988
Presymptomatic Neuropsychological Impairment in Huntington's Disease
Arch Neurol 45:769-773, Jason,G.W.,et al, 1988
Normal Caudate Glucose Metabolism in Persons at Risk for Huntington's Disease
Arch Neurol 44:254-257, Young,A.B.,et al, 1987
Reduced Cerebral Glucose Metabolism in Asymptomatic Subjects at Risk for Huntington's Disease
NEJM 316:357-362, Mazziotta,J.C.,et al, 1987
The Combined Use of Positron Emission Tomography & DNA Polymorphisms for Preclinical Detection of Huntington's Disease
Neurol 37:1441-1447, Hayden,M.R.,et al, 1987
Positron Emission Tomography in the Early Diagnosis of Huntington's Disease
Neurol 36:888-894, Hayden,M.R.,et al, 1986
Huntington's Disease, Pathogenesis & Management
NEJM 315:1267-1276, Martin,J.B.&Gusella,J.F., 1986
A DNA Polymorphism for Huntington's Disease Marks the Future
Arch Neurol 42:20-24, Wexler,N.S.,et al, 1985
Presymptomatic Testing for Huntington's Disease
JAMA 253:3286-3291, Bird,S.J., 1985
Genetic Prediction & Family Structure in Huntington's Chorea
BMJ 290:1929-1931, Harper,P.S.,et al, 1985
Genetic Testing in Huntington's Disease
Ann Neurol 16:511-513, Koller,W.C.,et al, 1984
A Genetic Marker for Huntington's Chorea
BMJ 287:1567-1568, Harper,P.S., 1983
Attitudes Of Those At Risk For Huntington's Disease Toward Presymptomatic Provocative Testing
NEJM 307:1406, McCormack,M.K., 1982
Huntington's Disease, CSF GABA Level in at-risk Individuals
Arch Neurol 35:728-730, Manyam,N.V.B.,et al, 1978
Clinical Presentation, Investigation Findings, and Outcomes of IgG4-Related Pachymeningitis,A Systematic Review
JAMA Neurol 82:193-199, Terrim,S.,et al, 2025
Methamphetamine-Induced Basal Ganglia Toxicity Presenting as Parkinsonism
Neurol 104:e213365, Yi,M.Y.,et al, 2025
Juvenile-Onset Dopa-Responsive Dystonia-Until It Isnt
Neurol 104:e213436, Paredes,N.C.,et al, 2025
Epilepsy in Patients with Primary CNS Lymphoma, Prevalence, Risk Factors, and Prognostic Significance
Neurol 103:e209748, Aboubakr,O.,et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Anticoagulation vs Antiplatelets Across Subgroups of Embolic Stroke of Undetermined Source
Neurol 103:e209949, Grannam,M.,et al, 2024
A 65-Year-Old Woman with Isolated Macroglossia as the Initial Presentation of a Rare Disease
Neurol 103:e210070, Lara,C.,et al, 2024
Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor, An Open-Label Clinical Trial
JAMA Neurol 81:939-946, Kaplitt,M.G.,et al, 2024
Photophobia as the Presenting Symptom of Internal Carotid Artery Dissection
Neuroophthalmology 44:315-318, Pellegrini,F.,et al, 2024